| Website | myokardia.com |
| Category | BioTech |
| Phone | (415) 766-3641 |
| Employees |
| TOTAL | $38M |
| FUNDING TOTAL | $38M |
| Series A, 9/12 Third Rock Ventures | $38M |
MyoKardia is dedicated to revolutionizing the treatment of cardiovascular disease. The company’s first programs include hypertrophic and dilated cardiomyopathy (HCM and DCM), which together afflict approximately 1 million people in the United States, and for which no novel therapeutics have been brought to market in over a decade.
